Funder: Alzheimers Drug Discovery
Due Date: December 8, 2017
The ADDF seeks to fill the critical translational funding gap between basic research and later stage drug development by funding promising preclinical drug discovery programs relevant to Alzheimer’s disease, related dementias, and cognitive aging.
Average Duration: 1-2 years
Average Award: $150,000-$600,000